Australians’ views and experience of personal genomic testing: survey findings from the Genioz study

Jacqueline Savard1,2,3, Chriselle Hickerton4, Rigan Tytherleigh4,5, Bronwyn Terrill3,6,7, Erin Turbitt4,5,12, Ainsley J. Newson2,3, Brenda Wilson8,13, Kathleen Gray9, Clara Gaff5,10, Anna Middleton11, Elaine Stackpoole5,14, Sylvia A. Metcalfe4,5

Received: 13 July 2018 / Revised: 22 October 2018 / Accepted: 22 November 2018 / Published online: 21 January 2019
© The Author(s) 2019. This article is published with open access

Abstract

Personal genomic tests (PGTs) for multiple purposes are marketed to ostensibly healthy people in Australia. These tests are generally marketed and purchased online commercially or can be ordered through a health professional. There has been minimal engagement with Australians about their interest in and experience with ordering a PGT. As part of a multistage, interdisciplinary project, an online survey (Stage 2 of the Genioz study) was available from May 2016 to May 2017. In total, 3253 respondents attempted the survey, with 2395 completed Australian responses from people with and without experience of having a PGT: 72% were female; 59% of the whole sample were undertaking/or had a university education; and, overall, age ranged from 18—over 80. A total of 571 respondents reported having had a genetic test, 373 of these classifiable as a PGT. A bivariate analysis suggests people who have undergone PGT in our sample were: women aged 25 and over; or in a high socioeconomic group, or have a personal or family diagnosis of a genetic condition (P ≤ 0.03). After a multivariate analysis, socioeconomic status and a genetic condition in the family were not of significance. The most common types of PGT reported were for carrier status and ancestry. Findings suggest greater awareness of, and an increasing demand for non-health related PGT in Australia. To support both consumers and health care professionals with understanding PGT results, there is a need for appropriate support and resources.

Introduction

It is now possible to obtain personal genomic information outside the context of a clinical or hospital setting, for example, through purchasing a personal genomic test.
(PGT). These tests can be grouped into health-related and recreational-associated tests. Health-related PGTs include those that test for a predisposition to certain conditions, responses to drugs, carrier status, and wellness (encompassing holistic aspects, such as diet and nutrition, intolerances, and allergy susceptibility) [1]. So-called recreational PGTs examine family relationships (including ancestry, ethnicity, and paternity), fitness and sporting abilities, physical and personality/behavioral traits, and testing for dating compatibility [2].

Markets for the different types of PGT are variable, depending on the geographical location and the regulatory environment in which the company and consumers are located. In Australia, the market for PGT has emerged at a slower pace compared to other countries [3]. Currently, Australian consumers can access PGT with or without a health care professional depending on the type of test they are seeking. They can obtain a test online from both onshore and overseas providers.

There are now several public attitude studies that explore the online personal genomics market [4, 5]. However, findings from these studies reflect the regions in which they were undertaken and are also a product of the social, political, and health care systems of the countries in which the research was conducted [4, 6, 7]. Research to date examining consumer knowledge, attitudes, and experiences of PGT in Australia has been limited. Findings from early research reported a small interest in direct-to-consumer PGT [8] with greater trust in receiving genomic information through a health care professional compared with a commercial company [9]. Accessibility of genomic tests has increased worldwide [10] and the presence of genomics on the national health policy agenda for Australia has also increased with a $500 million commitment over the next ten years to an Australian Genomics Health Futures Mission [11]. Therefore, while earlier studies offered some insights into Australians’ views, a wider examination of PGT in Australia from prospective and current consumers is due.

We sought to examine this area through the Genioz study, which was initiated in 2015. An outline of the Genioz study (www.genioz.net.au), is described elsewhere [12] but briefly this included five stages of data collection and analysis: focus groups, online survey, interviews, deliberative workshops, and ethical critique. In this paper, we report on the findings from the year-long nationwide survey (stage 2) quantitatively exploring Australians’ awareness, attitudes and experiences of PGT.

Materials and methods

The survey was approved by The University of Melbourne Human Research Ethics Committee (ID 1545806.1). At the end of the survey, participants could nominate whether they would like to participate in an interview about their views or experiences regarding personal genomic testing. This paper reports the survey findings only and interview data will be reported separately.

Survey design

A cross-sectional online survey was developed in REDCap comprising seven sections (see SF 1). Survey sections contained a mix of question and answer formats including: radio button (single answer), Likert scales, check-box/multiple response, and open-text boxes. Branching logic throughout the survey was based on respondents’ experiences of testing. Therefore, respondents may not have answered all the same questions and the time taken to complete the survey would have varied.

Survey questions were informed by the Genioz focus groups (stage 1), team expertise, and relevant published literature [4, 13–18]. A large portion of the survey focused on respondent experiences with PGT. However, the language used in the questions relating to experience with testing was framed as “genetic testing”. The research team felt this was a more familiar phrase for respondents to understand. Questions collected subjective attitude and opinion data, which are difficult to validate using traditional methods. A modified Delphi technique was used for face validity and consisted of two rounds to refine question inclusion [19]. Round 1 involved face-validity testing via a panel of 15 experts (including some members of the research team) who were asked to independently review each survey item based on the extent to which they were relevant to the aims of each section, and how difficult each item may be for a nonexpert to answer. Experts were from the following disciplines: health communication research, genetic counseling, law, public health and genetic research, genetics education, science communication, program evaluation, clinical genetics, and bioethics.

The panel’s round 1 Delphi responses were reviewed by the research team followed by modification of the survey items. Round 2 consisted of further face-validity testing via ten of the experts, followed by additional consultation within the research team leading to final item alteration. Research team members, as well as other colleagues, answered the survey in demonstration mode on different technological platforms to test for access and functionality. In addition, the survey content was piloted with participants from the initial Genioz focus groups [12] (who are members of the public and potential consumers of PGT). Key definitions were provided throughout the survey, for example: a definition of PGT, pharmacogenetics, and carrier testing.
Survey recruitment

A study website was developed to host information such as: study aims, frequently asked questions related to survey participation; a link to the Participant Information Statement and the embedded study survey. Once read, a respondent wishing to consent to participating (and having confirmed they were ≥18 years) could enter the survey. The survey was only available to those who had access to the Internet (accessible on multiple device types). Once the survey was completed, respondents could follow a link to some balanced information about PGT if they wanted more information.

A communication strategy developed by research team members guided the production of various online and hard copy materials to advertise the survey to members of the public (SF 2). Firstly, communication teams of the partnering institutes and universities assisted in promoting the launch of the website and survey via their online platforms and newsletters. To broaden recruitment opportunities, hard copy materials advertising the survey were sent to various community groups such as genealogical societies, recreational, and sport-related groups. Additionally, the survey was promoted on the social media platforms Facebook and Twitter [19]. Thought provoking questions with hashtags (such as: ‘How much do you think a person’s #genes contribute to their personality and other attributes? What are your thoughts about genetic tests that can be bought online? Tell us in our #survey) were posted and accompanied by images, cartoons or custom-made memes to pique the public’s interest and prompt survey participation. As such, recruitment of the survey used a mix of targeted, convenience and snowball sampling.

Our aim was to recruit a cross-section of Australian publics according to census data. At the 6-month recruitment point the research team noticed that some demographic characteristics were under represented. These included: a lower proportion of individuals from a lower education status; respondents from the 40-64-year-old age range, and males. Following approval of an ethics amendment and sign off on contract negotiations a market research company, Survey Sampling International (SSI), assisted recruitment from these groups. These data collection occurred at the 10-month recruitment point.

Data analysis

Survey data were prepared for analysis by removing blank and duplicate records. Respondents were included if they were ≥18 years and resided in Australia according to the postcode stated, therefore excluding people who reported they lived overseas. Complete and partial surveys were included for analysis; thus, n varies by question. Descriptive and logistic regression analyses were performed in Stata 14.2 [20].

Open-ended responses were recategorized once consensus was reached within the research team. Responses were either added to existing categories or a new category was created. For example, recoding was necessary to categorize whether people had had a PGT or a clinical test if they reported having had carrier testing, which can be offered in both contexts in Australia. Therefore, carrier tests were NOT classified as a PGT when respondents had indicated the following: (1) they either had a diagnosed genetic condition themselves and/or within their family/had a family history; or (2) they had carrier testing through a research program. Carrier tests were then classified as PGT if: there was NO diagnosed genetic condition in themselves or their family; or when asked about why they had carrier testing, they indicated one or more of the following reasons: (a) “I was planning to have children and wanted to know if there is a risk of passing on a genetic condition to my children”; (b) “I wanted this information for my grandchildren”; (c) “I thought I was at a higher risk because of my ethnic background”; (d) “I was curious”; and (e) “I didn’t think about it, I just did it”.

This survey was exploratory and not hypothesis driven. A Pearson chi-squared test was carried out to explore the relationship between age and test type; bivariate logistic regression sought to investigate which demographic variables and characteristics may be associated with experience of testing. Analyses were performed using multivariate logistic regression to adjust for potential confounding sociodemographic variables found to be different between those who had PGT and those who had not.

Results

Respondent demographics

From May 2016 to May 2017, there were 3253 attempts to start the survey. Of these, 2841 were unique attempts by respondents living in Australia, with 2395 completed surveys. Respondents living overseas (n = 101 from 32 countries) were excluded from analysis. The demographic characteristics of respondents are described in Table 1. Of respondents who completed the demographic section, 72% were women. The age range was from 18 years to over 80 and 59% of the whole sample had either previously studied or were studying at university. By comparison with the Australian Bureau of Statistics 2011 census data (SF 3), our sample contains a greater proportion of respondents from higher socioeconomic indexes for areas (SEIFA) categories and captured a greater proportion of respondents from the age categories of 20–24 years and 55–65 years (SF 4).

Of the respondents who answered questions about their occupation, 420 (14.9%) confirmed they worked in life
sciences and/or genomics. Overall, 384 (13.6%) respondents reported having a diagnosed genetic condition themselves and 680 (24.1%) reported knowing about a diagnosed genetic condition within their family. Knowledge questions were answered well overall, with a median of 12 out of 15 questions answered correctly (See SF 5, Boxplot of average median score).

Respondents’ experience with testing

In this sample, 571 individuals (22.4%) reported having had a genetic test. A further 1979 (77.6%) had never had a genetic test. Of the 571 who had testing, 373 (65.3%) had a PGT as defined by the research team. Ancestry and carrier testing were the two most common types of testing reported by respondents who stated having any type of test (see Fig. 1). The most common way testing was arranged was by purchasing by self, online (SF 6). This may reflect the high volume of ancestry testing reported, which is usually purchased online.

Results of a bivariate logistic regression analysis exploring the relationship between demographics and respondents who had reported having a PGT are shown in Table 2 (this includes carrier testing as a PGT, n = 373). The demographic characteristics showing an association with having pursued PGT include: being female (P = 0.002); belonging to one of two distinct age groups, either 25–49 (P < 0.001) or over 50 (P < 0.001); living in a SEIFA in the highest quintile (P = 0.03) (indicating high socio-economic advantage); currently studying at university or having been university educated (P < 0.001); working in the field of genomics and/or the life sciences (P ≤ 0.001); being a parent (including currently pregnant) (P < 0.001); having a diagnosed genetic condition in self (P < 0.001); or having a diagnosed genetic condition in the family (P < 0.001). A multivariate logistic regression was conducted to account for potentially confounding variables. From this analysis, the variables of SEIFA and having a diagnosed genetic condition in the family were no longer associated with having had a PGT (see Table 2 adjusted odds ratio).

A second bivariate logistic regression was conducted to determine if carrier testing had an impact on the results. In this survey, 36 respondents identified they either had a personal or family history of a genetic condition and had indicated they had carrier testing only and for reproductive reasons; these records were excluded from analysis to see if they influenced relationships between variables and having had a PGT (n = 337). As shown in Supplementary Table 1, there appears to be no effect on the relationships when these respondents were removed from analysis.

The Pearson’s chi-squared test indicated there is a significant relationship between age and type of test for
respondents who reported having undergone testing \( (n = 571) \). Results suggest respondents aged 20\(–\)49 are more likely to have had carrier testing \( (77.01, df = 1, P < 0.0001) \) and respondents aged 50\(+\) are more likely to have had ancestry testing \( (43.18, df = 1, P < 0.0001) \).

**Perceived barriers to testing**

According to respondents who had not had testing at the time of completing the survey, more than 50\% of respondents indicated that they had never thought about PGT. However, the largest barrier to pursuing testing was cost (Fig. 2). Additional barriers included: not knowing how to arrange such a test, potential negative impacts for self or family and concerns about third party access or discrimination.

**Seeking help with interpreting test results**

Regardless of their prior experiences with testing, the top three sources people reported they would approach for help understanding their results (for both health and nonhealth tests) were: a GP/primary care/family physician; a health care professional who specializes in the relevant area; or an independent genetic specialist (for example, a clinical geneticist or a genetic counselor) (Fig. 3).

**Satisfaction with testing**

At the end of the survey, respondents who had not previously had a genetic test were asked whether they would consider testing in the future and responses were compared to those given earlier in the survey. Of the 1866 who answered this question, 1081 \( (57.9\%) \) did not change their mind about whether they would consider testing or not, and 785 \( (42.1\%) \) did register a change in mind (see Fig. 4).

Of the 785 respondents who changed their mind, 657 respondents who initially did not consider testing changed their mind to either: now considering testing \( (n = 304, 46.3\%) \); or to “unsure” if they would consider testing \( (n = 353, 53.7\%) \). Respondents who changed their mind to now considering testing, indicated the types of tests they became interested in (could tick multiple options): for conditions that are serious but preventable \( (n = 252) \); carrier testing \( (n = 227) \); ancestry testing \( (n = 180) \); for conditions that are serious and not preventable \( (n = 171) \); pharmacogenetics \( (n = 170) \); nutrition/wellness \( (n = 158) \); for conditions that are not serious \( (n = 138) \); fitness testing \( (n = 136) \); testing for traits \( (n = 114) \); and relationship testing \( (n = 76) \).
The remaining 128 who changed their mind did so from initially saying yes, they have considered testing to either:

- no longer considering testing (n = 34, 26.6%) or “unsure” if they would consider testing (n = 94, 73.4%).

**Table 2** Bivariate logistic regression and multivariate logistic regression analysis of demographics and testing experience with carrier testing included as a PGT

| Variable | Had PGT n (%) | Not had PGT n (%) | Unadjusted odds ratio [95% CI] | P value | Adjusted odds ratio [95% CI] | P value |
|----------|---------------|--------------------|-------------------------------|---------|-------------------------------|---------|
| **Age**  |               |                    |                               |         |                               |         |
| 50+      | 222 (20.7)    | 851 (79.3)         | ref.                          |         |                               |         |
| 25–49    | 140 (14.8)    | 808 (85.2)         | 0.7 [0.5–0.8]                 | <0.001  |                               |         |
| 18–24    | 11 (3.3)      | 320 (96.7)         | 0.1 [0.07–0.5]                | 0.001   |                               |         |
| **Sex**  |               |                    |                               |         |                               |         |
| Male     | 85 (12.2)     | 610 (87.8)         | ref.                          |         |                               |         |
| Female   | 287 (17.5)    | 1357 (82.5)        | 1.5 [1.2–2.0]                 | 0.002   | 1.6 [1.2–2.1]                 | 0.001   |
| **SEIFA (IRSAD)** | | | | | | |
| First to fourth quintiles | 212 (14.7) | 1235 (85.3) | ref. | | | |
| Fifth quintile | 161 (18.1) | 730 (81.9) | 1.3 [1.0–1.6] | 0.03 | 1.2 [0.9–1.5] | 0.1 |
| **Education** | | | | | | |
| Never studied at university | 115 (11.9) | 863 (88.2) | ref. | | | |
| Currently studying/completed university | 256 (18.7) | 1 115 (83.0) | 1.7 [1.4–2.2] | <0.001 | 2.3 [1.8–3.1] | <0.001 |
| **Working in genomics and/or life sciences** | | | | | | |
| No | 333 (15.0) | 1881 (85.0) | ref. | | | |
| Yes | 40 (18.6) | 98 (81.4) | 2.3 [1.6–3.4] | <0.001 | 2.6 [1.7–3.1] | <0.001 |
| **Parent** | | | | | | |
| Yes/No, I’m currently pregnant | 273 (19.9) | 1097 (80.1) | ref. | | | |
| No | 100 (10.2) | 882 (89.8) | 0.5 [0.4–0.6] | <0.001 | 0.5 [0.4–0.7] | <0.001 |
| **Adopted** | | | | | | |
| No/don’t know | 358 (15.7) | 1926 (84.3) | ref. | | | |
| Yes | 13 (24.5) | 40 (75.5) | 1.7 [0.9–3.3] | 0.09 | | |
| **Genetic condition in self** | | | | | | |
| No | 281 (13.5) | 1804 (86.5) | ref. | | | |
| Yes | 92 (34.5) | 175 (65.5) | 3.4 [2.5–4.5] | <0.001 | 2.9 [2.1–4.1] | <0.001 |
| **Genetic condition in family** | | | | | | |
| No | 252 (13.6) | 1601 (86.4) | ref. | | | |
| Yes | 121 (24.2) | 378 (75.8) | 2.0 [1.6–2.6] | <0.001 | 1.3 [1.0–1.7] | 0.09 |
| **Self-reported health** | | | | | | |
| Fair/poor/unknown | 66 (16.2) | 341 (83.8) | ref. | | | |
| Excellent/very good/good | 307 (15.8) | 1 638 (84.2) | 1.0 [0.7–1.3] | 0.8 | | |

aCarrier tests were classified as PGT when:

1. There was NO diagnosed genetic condition in themselves
2. There was NO diagnosed genetic condition in their family
3. When asked about why they had carrier testing, they indicated one or more of the following reasons:
   a. I was planning to have children and wanted to know if there is a risk of passing on a genetic condition to my children
   b. I wanted this information for my grandchildren
   c. I thought I was at a higher risk because of my ethnic background
   d. I was curious
   e. I didn’t think about it, I just did it

bAge categories are structured to reflect the focus group categories from stage one of the Genioz research study

cThese questions were optional in the survey

**Discussion**

This Australian study aimed to collect data about knowledge, attitudes and experiences with PGT. Our sample is
unique because it captures respondents with and without experiences of PGT when the visibility and availability of testing was just beginning to increase in Australia.

Statistical analysis of respondents’ experiences with PGT (excluding clinical testing) indicated an association with the following characteristics: being female, having a university education, and having a genetic condition diagnosed in oneself. These findings are similar to other quantitative research where: respondents were likely to have a family history of a genetic condition [21]; were highly educated; and from a high socioeconomic status [22]. However, it is important to note that question differences, along with recruitment strategies between cohorts prevent direct comparisons between the studies. Our findings offer a distinct Australian view, an international perspective that has been notably absent in systematic reviews of the empirical literature [23, 24].

The Genioz study offers a perspective on PGT that differs from the published literature for four reasons. First, Australia has a hybrid health care system, such that publicly funded health care is available to eligible individuals, but it can be supplemented by private health insurance [25]. Secondly, there is a federal prohibition on advertising prescription drugs and medical devices direct-to-consumers [26], which includes the provision of health-related direct-to-consumer genetic tests. In 2017, there was a change to
Australian standards, such that for a laboratory to provide genetic susceptibility and genetic predisposition information for conditions, requires NATA (National Association of Testing Authorities; Australia) certification and registration to the Australian Register of Therapeutic Goods [27]. Thirdly, during the time the survey was available to respondents, an Australian-focused ancestry testing product was promoted via television, print and online advertising [2, 28]. This was in conjunction with a television program featuring Australian personalities exploring their ancestral origins with PGT [29]. This event coincided with the survey launch and subsequently, ancestry testing was the second most popular type of testing Genioz respondents had purchased. Finally, previous empirical research has found that Australians are more comfortable seeking health-related genetic information from a health care professional instead of a commercial company [9]. This may contribute to why health-related PGT was not reported as a popular type of testing by survey respondents.

While our sample recorded ancestry testing as the second most popular test type, the most reported by respondents was carrier testing. Findings indicate that in our sample, respondents aged 25–49 years were more likely to have pursued a form of carrier testing, while participants aged ≥50 years were most likely to have pursued ancestry testing. This potentially reflects goals and interests of the respective age groups; for example, family planning in the younger cohort and genealogical research in the older cohort. However, it should be noted that at present, there is not a recognized carrier screening program that forms a part of “regular” clinical care in Australia, but awareness of carrier testing and screening is increasing [30]. As a result, if a consumer wanted carrier testing in the absence of a family history, they are likely to seek a commercially offered and marketed test: a PGT.

A pivotal issue within this study was the difficulty of how to classify different types of genetic testing as a PGT or not PGT. Previous labeling of PGTs as either health- or nonhealth-related are no longer sufficient due in part to the increasing after-market applications that allow people to perform further analysis on their raw data [31]. Thus, boundaries are becoming blurred between health-related and nonhealth-related genomic information and the different ways it could be used [32]. These different uses of genomic information raise pragmatic concerns about who consumers can seek guidance and assistance from when they initially receive PGT results and/or additional results based on their own further analysis [3].

Issues can arise when consumers purchase genomic information from a commercial company and bring their results into a public health care system. For example, cost implications, misinterpretation of results, and limited expertise of nongenetic health professionals. Some companies do provide educational materials on their websites and details for their consumers to contact genetic counseling services (at their own expense). However, the resources can be variable. Within our sample, respondents reported that it was most appropriate to seek help with understanding PGT results from independent health professionals. A potential consequence of this approach means extra pressure on an already over-burdened health care system when PGTs are brought in by a consumer for further explanation/consultation [33]. The current support structures and systems will need to evolve to support these types of consultations. Extended findings from the Genioz study [34], along with scholarship in the UK and the US suggest genetic counselors are well placed to support consumers of PGT [35, 36].

While most research has focused on the experiences consumers have had with testing, there is still limited scholarship exploring views by consumers who have not had testing [37, 38]. From the change-of-mind data collected here, it appears the survey had an impact on a select group of respondents who reported a change in their contemplation about testing. It was beyond the scope of the study to measure whether the survey tool was an intervention, but it does suggest that the process of completing the survey increased awareness of PGT. Subsequent stages of the Genioz study [12] explore attitudes towards and experiences with PGT in greater depth, and how facilitated engagement may impact upon views on testing and the use of personal genomics.

Our survey findings are limited in several ways. Most respondents in this study were women. This is in part reflective of our online recruitment strategies, given that other studies have also reported that women were over-

---

**Fig. 4** Respondents’ (not tested) end of survey responses to whether they would consider having a test in the future.
represented [38–40] and that they are more likely to complete surveys they have found through social media [41]. Also, possibly reflective of our recruitment strategy, 15% of our sample reported that at the time they completed the survey they were working in a genomics-focused role. The survey collected self-reported data, which has been shown to contain inaccuracies [42]. In addition, given the structure, order of content and the length of the survey, biases may also contribute to the discrepancies in the data. These data represent a cross-section of a single time point and may not be reflective of people’s changing values and perspectives. Finally, as Australia has a population distribution across a vast landscape, connectivity to the Internet in some regions is variable, despite a high reported use of the Internet according to recent census data [43]. As the survey was only offered online, this would have made it difficult for some areas to be accessed for sampling purposes.

In conclusion, this survey contributes novel findings to an international perspective on personal genomics. Aside from carrier testing, ancestry was the most popular type of PGT reported. As the demand for PGT in Australia increases, our findings are timely and relevant. Importantly, there appear to be blurring boundaries as to what constitutes a PGT and how the generated genomic information can be used. With this increasing PGT market in Australia there is a need for appropriate support and resources for consumers and health care professionals to help both understand and make sense of the results. The survey findings were used to contribute to the subsequent stages of the Genioz study and the development of engagement tools used in further research.

Acknowledgments We would like to acknowledge the contributions of Luke Stevens, Susan Donath, Susanna Vidmar, Erin Tutty, Mark Adams, Elisa Pettorossi, Ollie Spray, and Nicole Gardner to the work described in this manuscript. We’d also like to acknowledge the experts who contributed their time and knowledge to the Delphi process and the Genioz Advisory Group for assistance with promoting the survey.

Funding Funding was provided through an Australian Research Council Discovery Project grant (DP150100597) and was also supported financially by the Victorian Government Operational Infrastructure support program, The Garvan Institute of Medical Research and the University of Sydney Network on Bodies, Organs and Tissues. This work was also supported by Wellcome Grant 206194 paid to Society and Ethics Research, Connecting Science. Ainsley Newson is financially by the Victorian Government Operational Infrastructure Support program, The Garvan Institute of Medical Research and the University of Sydney Network on Bodies, Organs and Tissues.

Compliance with ethical standards

Conflict of interest During this research, Bronwyn Terrill held a 0.2 FTE position with Genome.One, a commercial, wholly owned subsidiary of the Garvan Institute of Medical Research that offers clinically accredited personal genomic testing. The remaining authors declare that they have no conflict of interest.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Covolo L, Rubinelli S, Ceretti E, Gelatti U. Internet-based direct-to-consumer genetic testing: a systematic review. J Med Internet Res. 2015;17:e279.
2. Phillips AM. Only a click away—DTC genetics for ancestry, health, love…and more: a view of the business and regulatory landscape. Appl Transl Genom. 2016;8(Supplement C):16–22.
3. Allyse MA, Robinson DH, Ferber MJ, Sharp RR. Direct-to-consumer testing 2.0: emerging models of direct-to-consumer genetic testing. Mayo Clin Proc. 2018;93:113–20.
4. Carere DA, Kraft P, Kaphingst KA, Roberts JS, Green RC. Consumers report lower confidence in their genetics knowledge following direct-to-consumer personal genomic testing. Genet Med. 2016;18:65.
5. Stewart KF, Wesselius A, Schreurs MA, Schols AM, Zeegers MP. Behavioural changes, sharing behaviour and psychological responses after receiving direct-to-consumer genetic test results: a systematic review and meta-analysis. J Community Genet. 2017;9:1–18.
6. Vayena E, Gourna E, Streuli J, Hafen E, Prainsack B. Experiences of early users of direct-to-consumer genomics in Switzerland: an exploratory study. Public Health Genom. 2012;15:352–62.
7. Borry P, Cornel MC, Howard HC. Where are you going, where have you been: a recent history of the direct-to-consumer genetic testing market. J Community Genet. 2010;1:101–6.
8. Savard J, Mooney-Somers J, Newson A, Kerridge I. Australians’ knowledge and perceptions of direct-to-consumer personal genome testing. Intern Med J. 2014;44:27–31.
9. Critchley C, Nicol D, Oltowski M, Chalmers P. Direct reaction to direct-to-consumer online genetic tests: Comparing attitudes, trust and intentions across commercial and conventional providers. Public Underst Sci. 2014;23:731–50.
10. Roberts J, Middleton A. Genetics in the 21st century: implications for patients, consumers and citizens. Flinders Research. 2017;6.
11. Department of Health, Commonwealth of Australia. National Health and Medical Industry Growth Plan—Australian Genomics Health Futures Mission Canberra, ACT—2018. Available from: http://www.health.gov.au/internet/budget/publishing.nsf/Content/budget2018-factsheet65.htm. Cited 18 June 2018.
12. Metcalfe SA, Hickerton C, Savard J, et al. Australians’ views on personal genomic testing: focus group findings from the Genioz study. Eur J Hum Genet. 2018;26;1101–12.
13. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36): I. Conceptual framework and item selection. Med Care. 1992;30:473–83.
14. Henneman L, Timmermans DR, Van, der Wal G. Public experiences, knowledge and expectations about medical genetics and the use of genetic information. Public Health Genom. 2004;7:33–43.
15. Molster C, Charles T, Samanek A, O’Leary P. Australian study on public knowledge of human genetics and health. Public Health Genom. 2009;12:84–91.
16. Smerecnik C, Mesters I, De Vries N, De Vries H. Applying a theory-based framework to understand public knowledge of genetic risk factors: a case for the distinction between how-to knowledge and principles knowledge. Public Health Genom. 2011;14:259–70.
17. Haga SB, Barry WT, Mills R, et al. Public knowledge of and attitudes toward genetics and genetic testing. Genet Test Mol Biomark. 2013;17:327–35.
18. Zhang SC, Bruce C, Hayden M, Rieder MJ. Public perceptions of pharmacogenetics. Pediatrics. 2014;133:e1258–67.
19. Middleton A, Bragin E, Parker M. Finding people who will tell you their thoughts on genomics—recruitment strategies for social sciences research. J Community Genet. 2014;5:291–302.
20. StataCorp. Stata Statistical Software. 14 ed. College Station, TX: StataCorp; 2015.
21. Meisel SF, Carere DA, Wardle J, et al. Explaining, not just predicting, drives interest in personal genomics. Genome Med. 2015;7:1–7.
22. Carere DA, Couper MP, Crawford SD, et al. Design, methods, and participant characteristics of the Impact of Personal Genomics (PGen) Study, a prospective cohort study of direct-to-consumer personal genome testing customers. Genome Med. 2014;6:96–106.
23. Goldsmith L, Jackson L, O’Connor A, Skirton H. Direct-to-consumer genomic testing: systematic review of the literature on user perspectives. Eur J Hum Genet. 2012;20:811–6.
24. Roberts JS, Ostergren J. Direct-to-consumer genetic testing and personal genomics services: a review of recent empirical studies. Curr Genet Med Rep. 2013;1:182–200.
25. Australian Bureau of Statistics. Health care delivery and financing Canberra. 2015. Available from: http://www.abs.gov.au/AUSSTATS/abs@.nsf/Lookup/by%20Subject/1301.0–2012–Main%20Features–Health%20care%20delivery%20and%20financing–235. Cited 26 March 2018.
26. Therapeutic Goods Administration. Regulation of therapeutic goods advertising in Australia Canberra: Therapeutic Goods Administration. 2011. Available from: https://www.tga.gov.au/regulation-therapeutic-goods-advertising-australia. Cited 04 May 2018.
27. Therapeutic Goods Administration. Therapeutic Goods (Medical Devices) Regulations 2002 Canberra: Therapeutic Goods Administration. 2017. Available from: https://www.legislation.gov.au/Details/F2017C00534. Cited 18 May 2018.
28. More Australians turn to home DNA kits to trace their family histories [Internet]. News Corp Australia Network. 2016. Available from: http://www.news.com.au/technology/more-australians-turn-to-home-dna-kits-to-trace-their-family-histories/news-story/a9d22a75d1bd87d0770b85fa26d3c855. Cited 26 March 2018.
29. Permezel B. DNA Nation. In: Permezel B, editor. Sydney, Australia: SBS International; 2016. p. 60min
30. Metcalf SA, Bittles AH, O’Leary P, Emery J. Australia: public health genomics. Public Health Genom. 2009;12:121–8.
31. Van Der Wouden CH, Carere DA, Maitland-Van Der Zee AH, Ruffin MT, Roberts JS, Green RC. Consumer perceptions of interactions with primary care providers after direct-to-consumer personal genomic testing. Ann Intern Med. 2016;164:513–22.
32. Smart A, Bolnick DA, Tutton R. Health and genetic ancestry testing: time to bridge the gap. BMC Med Genom. 2017;10:3.
33. Rockwell K. Direct-to-consumer medical testing in the era of value-based care. J Am Med Assoc. 2017;317:2485–6.
34. Metcalf S, Hickerton C, Savard J, et al. Australians’ perspectives on support around use of personal genomic testing: findings from the Genioz Study. Eur J Med Genet. 2018; Nov 13, online ahead of print.
35. Middleton A, Mendes A, Benjamin CM, Howard H. Direct-to-consumer genetic testing: where and how does genetic counseling fit? Pers Med. 2017;14:249–57.
36. Kirkpatrick BE, Rashkind MD. Ancestry testing and the practice of genetic counseling. J Genet Couns. 2017;26:6–20.
37. Egglestone C, Morris A, O’Brien A. Effect of direct-to-consumer genetic tests on health behaviour and anxiety: a survey of consumers and potential consumers. J Genet Couns. 2013;22:565–75.
38. Wasson K, Sanders T, Hogan N, Cherny S, Helzlsouer K. Primary care patients’ views and decisions about, experience of and reactions to direct-to-consumer genetic testing: a longitudinal study. J Community Genet. 2013;4:495–505.
39. Blosso CS, Schork NJ, Topol EJ. Effect of direct-to-consumer genomewide profiling to assess disease risk. New Engl J Med. 2011;364:524–34.
40. McBride CM, Alford SH, Reid RJ, Larson EB, Baxevanis AD, Brody LC. Characteristics of users of online personalized genomic risk assessments: implications for physician-patient interactions. Genet Med. 2009;11:582–7.
41. Middleton A, Bragin E, Morley K, Parker M. Online questionnaire development: using film to engage participants and then gather attitudes towards the sharing of genomic data. Soc Sci Res. 2014;44:211–23.
42. Stone AA, Bachrach CA, Jobe JB, Kurtzman HS, Cain VS. The science of self-report: implications for research and practice. 1st ed. Hove: Psychology Press; 1999.
43. Australian Bureau of Statistics. 8153.0—Internet activity, Australia, June 2015 Canberra (AU). 2015. Available from: http://www.abs.gov.au/AUSSTATS/abs@.nsf/allprimarymainfeatures/5F5A511B54B5E656CA257F8C0013095A?opendocument. Cited 18 June 2018.